Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases

Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyel...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology Vol. 8; p. 529
Main Authors: Peschl, Patrick, Bradl, Monika, Höftberger, Romana, Berger, Thomas, Reindl, Markus
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 08.05.2017
Subjects:
autoantibodies
demyelination
Immunology
inflammation
MOG
myelin oligodendrocyte glycoprotein
MOG
myelin oligodendrocyte glycoprotein
inflammation
autoantibodies
demyelination
ISSN:1664-3224, 1664-3224
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies (Abs), as a biomarker in MS. But with improved detection methods using different expression systems to detect Abs in patients' samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in -methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes. Whereas MOG Abs are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD, recurrent ON, or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG Ab-positive cases as a new disease entity. Neuropathologically, the presence of MOG Abs is characterized by MS-typical demyelination and oligodendrocyte pathology associated with Abs and complement. However, it remains unclear whether MOG Abs are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG Abs and their role in the immunpathogenesis of inflammatory demyelinating disorders.
AbstractList Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies (Abs), as a biomarker in MS. But with improved detection methods using different expression systems to detect Abs in patients' samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in N-methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes. Whereas MOG Abs are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD, recurrent ON, or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG Ab-positive cases as a new disease entity. Neuropathologically, the presence of MOG Abs is characterized by MS-typical demyelination and oligodendrocyte pathology associated with Abs and complement. However, it remains unclear whether MOG Abs are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG Abs and their role in the immunpathogenesis of inflammatory demyelinating disorders.Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies (Abs), as a biomarker in MS. But with improved detection methods using different expression systems to detect Abs in patients' samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in N-methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes. Whereas MOG Abs are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD, recurrent ON, or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG Ab-positive cases as a new disease entity. Neuropathologically, the presence of MOG Abs is characterized by MS-typical demyelination and oligodendrocyte pathology associated with Abs and complement. However, it remains unclear whether MOG Abs are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG Abs and their role in the immunpathogenesis of inflammatory demyelinating disorders.
Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies (Abs), as a biomarker in MS. But with improved detection methods using different expression systems to detect Abs in patients' samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in -methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes. Whereas MOG Abs are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD, recurrent ON, or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG Ab-positive cases as a new disease entity. Neuropathologically, the presence of MOG Abs is characterized by MS-typical demyelination and oligodendrocyte pathology associated with Abs and complement. However, it remains unclear whether MOG Abs are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG Abs and their role in the immunpathogenesis of inflammatory demyelinating disorders.
Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of myelin sheaths and oligodendrocyte membranes. This makes MOG a potential target of cellular and humoral immune responses in inflammatory demyelinating diseases. Due to its late postnatal developmental expression, MOG is an important marker for oligodendrocyte maturation. Discovered about 30 years ago, it is one of the best-studied autoantigens for experimental autoimmune models for multiple sclerosis (MS). Human studies, however, have yielded controversial results on the role of MOG, especially MOG antibodies (Abs), as a biomarker in MS. But with improved detection methods using different expression systems to detect Abs in patients’ samples, this is meanwhile no longer the case. Using cell-based assays with recombinant full-length, conformationally intact MOG, several recent studies have revealed that MOG Abs can be found in a subset of predominantly pediatric patients with acute disseminated encephalomyelitis (ADEM), aquaporin-4 (AQP4) seronegative neuromyelitis optica spectrum disorders (NMOSD), monophasic or recurrent isolated optic neuritis (ON), or transverse myelitis, in atypical MS and in N-methyl-d-aspartate receptor-encephalitis with overlapping demyelinating syndromes. Whereas MOG Abs are only transiently observed in monophasic diseases such as ADEM and their decline is associated with a favorable outcome, they are persistent in multiphasic ADEM, NMOSD, recurrent ON, or myelitis. Due to distinct clinical features within these diseases it is controversially disputed to classify MOG Ab-positive cases as a new disease entity. Neuropathologically, the presence of MOG Abs is characterized by MS-typical demyelination and oligodendrocyte pathology associated with Abs and complement. However, it remains unclear whether MOG Abs are a mere inflammatory bystander effect or truly pathogenetic. This article provides deeper insight into recent developments, the clinical relevance of MOG Abs and their role in the immunpathogenesis of inflammatory demyelinating disorders.
Author Höftberger, Romana
Bradl, Monika
Peschl, Patrick
Reindl, Markus
Berger, Thomas
AuthorAffiliation 1 Clinical Department of Neurology, Medical University of Innsbruck , Innsbruck , Austria
3 Institute of Neurology, Medical University of Vienna , Vienna , Austria
2 Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna , Vienna , Austria
AuthorAffiliation_xml – name: 1 Clinical Department of Neurology, Medical University of Innsbruck , Innsbruck , Austria
– name: 2 Department of Neuroimmunology, Center for Brain Research, Medical University of Vienna , Vienna , Austria
– name: 3 Institute of Neurology, Medical University of Vienna , Vienna , Austria
Author_xml – sequence: 1
  givenname: Patrick
  surname: Peschl
  fullname: Peschl, Patrick
– sequence: 2
  givenname: Monika
  surname: Bradl
  fullname: Bradl, Monika
– sequence: 3
  givenname: Romana
  surname: Höftberger
  fullname: Höftberger, Romana
– sequence: 4
  givenname: Thomas
  surname: Berger
  fullname: Berger, Thomas
– sequence: 5
  givenname: Markus
  surname: Reindl
  fullname: Reindl, Markus
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28533781$$D View this record in MEDLINE/PubMed
BookMark eNp1kstr3DAQxkVJaB7NvafiYy-71dO2eiiUPBdScknPqiyPHQVZ2kragv_7anfTkBQiJPT6vt8MzJygAx88IPSR4CVjrfwy2GnaLCkmzRJjQeU7dEzqmi8YpfzgxfkInaX0iMvgkjEm3qMj2grGmpYco18_ZnDWV3fOjqEH38dg5gzVtZtNWMeQwfqv1QUYu36AaP1Y6epexxFyVVwrPzg9TTqHOBfRtGPpvJVd2AQ6QfqADgftEpw97afo59Xl_fnN4vbuenX-_XZheE3zAgYqoSUDbwbRC95JrFvDu3IFM_B6EG3XdMQwTkzTgemJxDURtKllWQ0GdopWe24f9KNaRzvpOKugrdo9hDgqHbM1DpRsdKHThmhDeK-hI2VyURshJXDDCuvbnrXedBP0BnyO2r2Cvv7x9kGN4Y8SnGIhSQF8fgLE8HsDKavJJgPOaQ9hk1TJnpS0hWyL9NPLWM9B_pWoCPBeYGJIKcLwLCFYbRtB7RpBbRtB7RqhWOr_LMbmUpawzda6t41_ASQhut4
CitedBy_id crossref_primary_10_1016_j_msard_2022_104057
crossref_primary_10_1016_j_micinf_2022_105014
crossref_primary_10_1016_j_neuint_2018_04_009
crossref_primary_10_3390_jcm14072445
crossref_primary_10_1186_s42466_021_00145_w
crossref_primary_10_3390_brainsci12080995
crossref_primary_10_1016_j_jneuroim_2024_578351
crossref_primary_10_1016_j_msard_2018_01_007
crossref_primary_10_1038_s41582_018_0112_x
crossref_primary_10_3390_children6060075
crossref_primary_10_1002_chem_202004076
crossref_primary_10_3390_diagnostics13040687
crossref_primary_10_1016_j_jocn_2020_11_011
crossref_primary_10_1016_j_jpsychires_2023_03_030
crossref_primary_10_1186_s12974_019_1674_2
crossref_primary_10_3389_fneur_2022_746653
crossref_primary_10_1136_jnnp_2024_335579
crossref_primary_10_2478_amma_2021_0024
crossref_primary_10_1038_s41598_018_36578_8
crossref_primary_10_1016_j_jneuroim_2021_577702
crossref_primary_10_1016_j_msard_2018_07_025
crossref_primary_10_3389_fnins_2022_811371
crossref_primary_10_3389_fneur_2023_1188323
crossref_primary_10_17116_jnevro202312311147
crossref_primary_10_3389_fimmu_2023_1111719
crossref_primary_10_7759_cureus_56941
crossref_primary_10_1016_j_mjafi_2021_03_005
crossref_primary_10_1136_jnnp_2018_317969
crossref_primary_10_1038_s41467_025_61922_8
crossref_primary_10_1016_j_bmc_2019_03_038
crossref_primary_10_1016_j_jconrel_2022_02_009
crossref_primary_10_3389_fneur_2019_00868
crossref_primary_10_1016_j_msard_2019_05_006
crossref_primary_10_1097_ICU_0000000000000520
crossref_primary_10_1016_j_chemosphere_2022_137296
crossref_primary_10_1080_17425247_2021_2003327
crossref_primary_10_3389_fimmu_2022_1036200
crossref_primary_10_4103_neurol_india_Neurol_India_D_23_00631
crossref_primary_10_1016_j_neuroscience_2025_03_063
crossref_primary_10_1111_jnc_14339
crossref_primary_10_3389_fimmu_2023_1256480
crossref_primary_10_1007_s10072_020_04371_z
crossref_primary_10_2174_0118715303325979241206115417
crossref_primary_10_3389_fimmu_2025_1530977
crossref_primary_10_1177_11206721211028050
crossref_primary_10_3390_cimb44110388
crossref_primary_10_1007_s10787_020_00691_w
crossref_primary_10_2147_OPTH_S288224
crossref_primary_10_3389_fneur_2023_1216477
crossref_primary_10_1016_j_msard_2023_105405
crossref_primary_10_1186_s40478_017_0495_8
crossref_primary_10_1016_j_jneuroim_2019_577143
crossref_primary_10_3389_fimmu_2019_01189
crossref_primary_10_3389_fnmol_2020_00114
crossref_primary_10_1016_j_msard_2018_02_023
crossref_primary_10_1055_s_0040_1701371
crossref_primary_10_2147_IMCRJ_S315103
crossref_primary_10_1177_1756286420945135
crossref_primary_10_3389_fnins_2024_1357633
crossref_primary_10_1007_s12035_021_02547_y
crossref_primary_10_3390_v12060643
crossref_primary_10_3390_brainsci13010042
crossref_primary_10_1007_s00415_021_10611_9
crossref_primary_10_1111_ene_13668
crossref_primary_10_1016_j_msard_2021_103030
crossref_primary_10_1016_j_neurol_2018_04_003
crossref_primary_10_3389_fneur_2021_775181
crossref_primary_10_1016_j_msard_2023_105133
crossref_primary_10_1212_NXI_0000000000000702
crossref_primary_10_1016_j_expneurol_2020_113241
crossref_primary_10_1007_s00415_020_10236_4
crossref_primary_10_1007_s40629_018_0056_0
crossref_primary_10_3390_biom12050667
crossref_primary_10_3389_fped_2022_859932
crossref_primary_10_3390_molecules27113516
crossref_primary_10_3389_fimmu_2023_1162248
crossref_primary_10_3389_fneur_2018_00217
crossref_primary_10_1016_j_pediatrneurol_2022_05_004
crossref_primary_10_1093_brain_awab231
crossref_primary_10_1212_NXI_0000000000200059
crossref_primary_10_1016_j_autrev_2021_102921
crossref_primary_10_1212_NXI_0000000000000708
crossref_primary_10_3390_ijms241713368
crossref_primary_10_1016_j_bbi_2024_11_026
crossref_primary_10_1002_glia_23512
crossref_primary_10_1016_j_msard_2018_12_017
crossref_primary_10_12890_2025_005467
crossref_primary_10_1016_j_jbc_2023_103065
crossref_primary_10_1016_j_ajem_2023_04_031
crossref_primary_10_1007_s00112_017_0374_1
crossref_primary_10_1055_s_0041_1723955
crossref_primary_10_3389_fneur_2020_541146
crossref_primary_10_3389_fneur_2020_612304
crossref_primary_10_1016_j_bbrep_2025_102233
crossref_primary_10_1016_j_actbio_2019_08_036
crossref_primary_10_1111_cns_13193
crossref_primary_10_1007_s00415_021_10749_6
crossref_primary_10_3389_fimmu_2018_02753
crossref_primary_10_3389_fimmu_2023_1293100
crossref_primary_10_1016_j_jneuroim_2018_05_014
crossref_primary_10_7759_cureus_70518
crossref_primary_10_1212_CON_0000000000000742
crossref_primary_10_1093_emph_eoy002
crossref_primary_10_1016_j_msard_2019_101416
crossref_primary_10_2147_IDR_S375624
crossref_primary_10_1111_sji_13344
crossref_primary_10_1089_aid_2024_0053
crossref_primary_10_1002_bmc_4533
crossref_primary_10_1016_j_neuroscience_2024_04_004
crossref_primary_10_3389_fimmu_2022_996469
crossref_primary_10_1007_s13760_025_02787_y
crossref_primary_10_1111_dmcn_14594
crossref_primary_10_1007_s10354_022_00987_2
crossref_primary_10_1007_s40265_018_1039_7
crossref_primary_10_1007_s11940_021_00672_6
crossref_primary_10_1016_j_msard_2021_103216
crossref_primary_10_1007_s15007_018_1580_4
crossref_primary_10_1186_s12887_022_03679_3
crossref_primary_10_1097_WNO_0000000000001772
crossref_primary_10_3389_fimmu_2020_575451
crossref_primary_10_3389_fimmu_2024_1347767
crossref_primary_10_1097_WCO_0000000000000650
crossref_primary_10_1186_s12974_019_1521_5
crossref_primary_10_1080_01616412_2022_2124794
crossref_primary_10_3345_cep_2019_01305
crossref_primary_10_3390_ijms231911532
crossref_primary_10_1002_ana_25291
crossref_primary_10_3390_genes13112020
crossref_primary_10_1002_advs_202406364
crossref_primary_10_1016_j_msard_2023_104879
crossref_primary_10_1016_j_msard_2020_102018
crossref_primary_10_1186_s12868_022_00720_0
crossref_primary_10_1016_j_clineuro_2023_107850
crossref_primary_10_1097_RMR_0000000000000187
crossref_primary_10_3389_fneur_2019_00415
crossref_primary_10_1016_j_jaut_2019_04_013
crossref_primary_10_3389_fneur_2023_1137998
crossref_primary_10_1016_j_jns_2018_06_028
crossref_primary_10_1002_jev2_12397
crossref_primary_10_1007_s12035_020_02013_1
crossref_primary_10_1074_jbc_RA118_004825
crossref_primary_10_1080_10520295_2018_1482001
crossref_primary_10_1212_NXI_0000000000000919
crossref_primary_10_1016_j_msard_2024_106171
crossref_primary_10_1007_s10072_020_04379_5
crossref_primary_10_1007_s00401_020_02132_y
crossref_primary_10_1038_s41398_024_02915_x
crossref_primary_10_1186_s12974_018_1335_x
crossref_primary_10_1007_s40261_019_00793_6
crossref_primary_10_1016_j_msard_2020_101949
crossref_primary_10_3389_fimmu_2020_01188
crossref_primary_10_3389_fimmu_2021_686466
crossref_primary_10_1016_j_neurol_2018_01_378
crossref_primary_10_1093_nsr_nwaa099
crossref_primary_10_31083_j_fbl2911394
crossref_primary_10_3389_fimmu_2023_1224217
crossref_primary_10_1016_j_jns_2017_09_020
crossref_primary_10_1016_j_ajpath_2021_11_010
crossref_primary_10_1212_WNL_0000000000012175
crossref_primary_10_1016_j_jhep_2023_04_037
crossref_primary_10_1093_brain_awaa102
crossref_primary_10_1007_s11910_024_01344_z
crossref_primary_10_1007_s13204_022_02698_x
Cites_doi 10.1212/WNL.0b013e31826aac4e
10.1084/jem.20130699
10.1002/acn3.164
10.1177/1352458512466317
10.1007/s11481-013-9487-z
10.1186/2051-5960-2-35
10.1016/j.jneuroim.2016.02.004
10.1136/jnnp-2015-312676
10.1111/dmcn.13090
10.1002/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S
10.1084/jem.20021603
10.1016/0014-4886(68)90148-9
10.1177/1352458510389220
10.2169/internalmedicine.55.6122
10.1016/j.braindev.2016.02.004
10.1083/jcb.103.6.2439
10.1111/j.1750-3639.1996.tb00857.x
10.1016/S0165-5728(00)00360-X
10.4049/jimmunol.161.9.4480
10.1034/j.1600-065x.2001.1830113.x
10.1177/1352458515587751
10.1073/pnas.0607283103
10.1111/imm.12155
10.1212/NXI.0000000000000335
10.1002/1521-4141(200012)30:12<3663::AID-IMMU3663>3.0.CO;2-7
10.1111/ene.12759
10.1111/j.1471-4159.2006.04053.x
10.1111/j.1750-3639.1998.tb00194.x
10.1038/nature10554
10.1016/j.molmed.2010.11.006
10.2169/internalmedicine.55.5727
10.2337/dc15-0101
10.1172/JCI15861
10.1111/j.1471-4159.1986.tb00679.x
10.4049/jimmunol.1300452
10.3390/v8020051
10.1038/ni833
10.1212/WNL.0b013e318228c0b1
10.1212/NXI.0000000000000040
10.1172/JCI28334
10.1016/0165-5728(95)00124-7
10.1177/1352458515622986
10.1056/NEJMoa063602
10.1212/NXI.0000000000000175
10.1177/1352458515591071
10.1186/s12883-014-0224-x
10.1016/j.jneuroim.2009.05.017
10.1038/nm.1975
10.1002/eji.200425842
10.1001/jamaneurol.2014.3602
10.1007/s00401-013-1116-7
10.1002/eji.1830250419
10.1007/s00401-016-1631-4
10.1172/JCI118368
10.1038/nrneurol.2013.118
10.1111/j.1440-1789.2010.01131.x
10.1016/j.jaut.2010.01.003
10.1016/S0165-5728(97)00019-2
10.1155/2015/673503
10.1084/jem.20090299
10.1084/jem.188.1.169
10.1186/s12974-016-0720-6
10.1136/jnnp-2013-306411
10.1016/j.jneuroim.2014.03.001
10.1055/s-0036-1583184
10.1523/JNEUROSCI.23-13-05461.2003
10.1016/0896-8411(89)90149-2
10.1002/1521-4141(200207)32:7<1905::AID-IMMU1905>3.0.CO;2-L
10.1007/s00415-015-7983-1
10.1172/JCI28330
10.1212/WNL.0000000000001370
10.1016/0165-5728(87)90031-2
10.1111/j.1471-4159.1979.tb11084.x
10.1046/j.1471-4159.1997.69010214.x
10.1212/NXI.0000000000000163
10.1111/ene.12898
10.1002/ana.21916
10.4049/jimmunol.165.2.1093
10.4049/jimmunol.171.1.455
10.1212/NXI.0000000000000012
10.4137/MRI.S19750
10.1016/S0140-6736(04)17551-X
10.1212/NXI.0000000000000081
10.1007/s11427-015-4997-y
10.1002/eji.1830250723
10.1542/peds.2015-1958
10.1186/s12974-016-0717-1
10.1111/j.1471-4159.1990.tb04173.x
10.4049/jimmunol.1102186
10.1002/eji.1830230627
10.1002/acn3.194
10.1212/NXI.0000000000000088
10.1212/WNL.0000000000002844
10.1186/s12974-016-0718-0
10.1002/eji.200737475
10.1016/j.molimm.2010.10.025
10.1084/jem.85.1.117
10.1001/jamaneurol.2013.5857
10.1038/347151a0
10.1177/1352458516631038
10.1128/JVI.05398-11
10.1084/jem.20122192
10.1136/jnnp-2015-311743
10.1002/ana.410370415
10.1212/NXI.0000000000000257
10.4049/jimmunol.180.3.1326
10.1136/jnnp-2014-308346
10.1073/pnas.122092499
10.1073/pnas.1519608113
10.1038/nm1488
10.1007/BF00686201
10.1016/0165-5728(92)90136-9
10.3109/08916939809003872
10.1002/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K
10.1111/j.1471-4159.1989.tb10930.x
10.4049/jimmunol.167.12.7119
10.2353/ajpath.2007.060893
10.1055/s-0034-1371179
10.1093/intimm/8.11.1667
10.1097/WNO.0b013e31823c9b6c
10.1186/s12974-016-0719-z
10.4049/jimmunol.1301296
10.1002/eji.200425050
10.1073/pnas.0510672103
10.4049/jimmunol.166.12.7588
10.1074/jbc.M413174200
10.1212/NXI.0000000000000225
10.1038/5941
10.1186/s12974-015-0256-1
10.1212/NXI.0000000000000022
10.1056/NEJMoa022328
10.1177/1352458515593406
10.1177/1352458514551455
10.1172/JCI3022
10.1111/j.1365-2567.2008.02955.x
10.1073/pnas.0607242103
10.1177/1352458514551454
10.1136/bmjopen-2015-007766
10.1002/jnr.490330123
10.1371/journal.pone.0110048
10.1177/1352458515614093
10.4049/jimmunol.163.1.40
10.4049/jimmunol.0801888
10.1136/jnnp-2014-310206
10.1093/intimm/dxg023
10.1212/WNL.0000000000000101
10.1097/NEN.0b013e31816a6851
10.1016/j.jaut.2003.09.001
10.1177/1352458514555785
10.1001/archneur.65.11.1527
10.1016/S0165-5728(00)00306-4
10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2
10.1001/archneurol.2011.2956
10.4049/jimmunol.1402236
10.1016/j.braindev.2014.02.002
10.1007/s00401-016-1559-8
10.1186/1742-2094-8-184
10.1016/j.jns.2013.08.034
10.1177/1352458514566666
10.1111/j.1471-4159.2007.04687.x
10.1016/j.expneurol.2008.12.027
10.1126/science.6362005
10.4049/jimmunol.116.5.1439
10.1083/jcb.201504106
10.1177/1352458512470310
10.1212/NXI.0000000000000131
10.4049/jimmunol.152.6.3183
10.4049/jimmunol.171.9.4934
10.1093/brain/awp321
10.1002/ana.410320212
10.1016/j.clim.2010.11.013
10.1007/s00415-016-8147-7
10.1073/pnas.0705894104
10.4049/jimmunol.154.10.5536
10.4049/jimmunol.153.10.4349
10.1186/s40478-015-0260-9
10.1073/pnas.0504979102
10.1016/S0165-5728(99)00133-2
10.1002/eji.201141863
10.1212/NXI.0000000000000089
10.1073/pnas.90.17.7990
10.4049/jimmunol.139.12.4016
10.2337/diabetes.54.suppl_2.S52
10.1074/jbc.M111.304246
10.1212/WNL.0b013e3181e04096
10.4049/jimmunol.172.1.661
10.1002/ana.24117
ContentType Journal Article
Copyright Copyright © 2017 Peschl, Bradl, Höftberger, Berger and Reindl. 2017 Peschl, Bradl, Höftberger, Berger and Reindl
Copyright_xml – notice: Copyright © 2017 Peschl, Bradl, Höftberger, Berger and Reindl. 2017 Peschl, Bradl, Höftberger, Berger and Reindl
DBID AAYXX
CITATION
NPM
7X8
5PM
DOA
DOI 10.3389/fimmu.2017.00529
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1664-3224
ExternalDocumentID oai_doaj_org_article_97a0a8271ac14daeb1eb1456c599e4c3
PMC5420591
28533781
10_3389_fimmu_2017_00529
Genre Journal Article
Review
GrantInformation_xml – fundername: Austrian Science Fund
  grantid: W1206 (signal processing in neurons)
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EBS
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RNS
RPM
ACXDI
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c462t-ef29e81f47f5d54b90a8c4b47fecf46f58b7b1c341c7becd190615276927670e3
IEDL.DBID DOA
ISICitedReferencesCount 180
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000400710400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1664-3224
IngestDate Fri Oct 03 12:51:23 EDT 2025
Tue Sep 30 16:38:24 EDT 2025
Fri Sep 05 08:44:31 EDT 2025
Thu Apr 03 07:08:54 EDT 2025
Tue Nov 18 21:18:28 EST 2025
Sat Nov 29 03:12:39 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords MOG
myelin oligodendrocyte glycoprotein
inflammation
autoantibodies
demyelination
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-ef29e81f47f5d54b90a8c4b47fecf46f58b7b1c341c7becd190615276927670e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Robert Weissert, University of Regensburg, Germany
Reviewed by: Tomas Per Olsson, Karolinska Institutet, Sweden; H.-Christian Von Büdingen, University of California San Francisco, USA
Specialty section: This article was submitted to Multiple Sclerosis and Neuroimmunology, a section of the journal Frontiers in Immunology
OpenAccessLink https://doaj.org/article/97a0a8271ac14daeb1eb1456c599e4c3
PMID 28533781
PQID 1901767598
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_97a0a8271ac14daeb1eb1456c599e4c3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5420591
proquest_miscellaneous_1901767598
pubmed_primary_28533781
crossref_primary_10_3389_fimmu_2017_00529
crossref_citationtrail_10_3389_fimmu_2017_00529
PublicationCentury 2000
PublicationDate 2017-05-08
PublicationDateYYYYMMDD 2017-05-08
PublicationDate_xml – month: 05
  year: 2017
  text: 2017-05-08
  day: 08
PublicationDecade 2010
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in immunology
PublicationTitleAlternate Front Immunol
PublicationYear 2017
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Lassmann (B22) 1988; 75
Molnarfi (B94) 2013; 210
Lalive (B114) 2011; 17
Symmonds (B139) 2015; 84
Piddlesden (B42) 1993; 143
Harrer (B53) 2009; 216
Genain (B104) 2001; 183
Probstel (B116) 2011; 77
Schluesener (B37) 1987; 139
Baekkeskov (B186) 1990; 347
Piccolo (B153) 2016; 263
Hoftberger (B100) 2015; 3
Spadaro (B136) 2015; 2
Lebar (B16) 1989; 2
Lalive (B109) 2006; 103
Morris (B140) 2015; 2
Herrera (B86) 2014; 7
Linington (B33) 1993; 23
Anderson (B81) 2012; 188
Titulaer (B126) 2014; 75
Ketelslegers (B147) 2015; 21
Rostasy (B121) 2013; 19
Pihoker (B190) 2005; 54
Numa (B150) 2016; 55
Jarius (B172) 2016; 22
Pollinger (B78) 2009; 206
Baumann (B154) 2016; 22
Körtvélyessy (B179) 2017; 4
Thulasirajah (B168) 2016; 47
Genain (B43) 1995; 96
Bourquin (B68) 2000; 30
Berger (B107) 2015; 22
Adelmann (B24) 1995; 63
Kezuka (B117) 2012; 32
Wenzlau (B188) 2007; 104
Mendel (B32) 1995; 25
Miyauchi (B129) 2014; 45
Young (B183) 2010; 133
Seil (B19) 1968; 22
Tanaka (B128) 2014; 270
Linington (B17) 1987; 17
Brok (B69) 2000; 165
de Graaf (B27) 2012; 287
Lebar (B20) 1976; 116
Chalmoukou (B146) 2015; 2
Waters (B141) 2015; 2
Berer (B98) 2011; 479
Ramanathan (B130) 2014; 1
Lechner (B169) 2016; 87
Massacesi (B103) 1995; 37
Akaishi (B162) 2016; 293
Scolding (B39) 1991; 72
Brilot (B112) 2009; 66
Linington (B4) 1988; 130
Woodhall (B123) 2013; 335
Probstel (B137) 2015; 12
Johns (B44) 1995; 154
Hjelmstrom (B92) 1998; 161
Delarasse (B1) 2006; 98
Marta (B26) 2005; 102
Jarius (B175) 2016; 13
Berer (B29) 2011; 48
Jagessar (B52) 2008; 67
Weissert (B62) 1998; 102
Lyons (B90) 1999; 29
Bettini (B79) 2009; 213
Marta (B48) 2003; 23
Saadoun (B57) 2014; 2
Ikeda (B142) 2015; 21
Kerlero de Rosbo (B31) 1995; 25
Berger (B105) 2003; 349
Guggenmos (B9) 2004; 172
Cong (B11) 2011; 85
Akaishi (B160) 2016; 87
Delarasse (B34) 2013; 140
Raine (B65) 1999; 46
Abdul-Majid (B66) 2000; 111
O’Connor (B110) 2007; 13
Ichikawa (B45) 1996; 8
Bourquin (B28) 2003; 171
Martini (B5) 1986; 103
Zhou (B50) 2006; 103
Mader (B55) 2011; 8
Flach (B58) 2016; 113
Jagessar (B82) 2012; 42
Di Pauli (B115) 2011; 138
Kitley (B119) 2012; 79
Nakajima (B143) 2015; 5
McLaughlin (B111) 2009; 183
Kerlero de Rosbo (B38) 1990; 55
Menon (B46) 1997; 69
Jarius (B176) 2016; 13
Marta (B7) 2005; 280
Smith (B73) 2005; 35
Palmer (B185) 1983; 222
von Budingen (B13) 2015; 210
von Budingen (B25) 2002; 99
Bettelli (B97) 2006; 116
Fillatreau (B93) 2002; 3
Reindl (B184) 2013; 9
Rabin (B187) 1994; 152
Kap (B76) 2008; 180
Siritho (B164) 2016; 22
Storch (B63) 1998; 8
Adachi (B151) 2016; 55
Kabat (B18) 1947; 85
Di Pauli (B149) 2015; 2
Sepulveda (B166) 2016; 263
Huppke (B120) 2013; 19
Brunner (B3) 1989; 52
Sato (B124) 2014; 82
Svensson (B96) 2002; 32
Azumagawa (B171) 2016; 38
Linington (B41) 1992; 40
t Hart (B102) 2015; 2
t Hart (B101) 2011; 17
Slavin (B61) 1998; 28
Lebar (B21) 1979; 32
Urich (B51) 2006; 103
Kinzel (B59) 2016; 132
Hacohen (B138) 2015; 2
Hacohen (B170) 2016; 58
Shetty (B35) 2014; 1
Litzenburger (B89) 1998; 188
Rostasy (B118) 2012; 69
van Pelt (B158) 2016; 23
Gardinier (B8) 1992; 33
Amor (B30) 1994; 153
Kerlero de Rosbo (B67) 2000; 110
Martinez-Hernandez (B134) 2015; 72
York (B80) 2010; 35
Bonifacio (B189) 2015; 38
von Budingen (B49) 2004; 34
Dale (B56) 2014; 1
Van der Goes (B47) 1999; 101
Devaux (B60) 1997; 75
Sun (B72) 2003; 15
Elong Ngono (B132) 2015; 2015
Forsthuber (B88) 2001; 167
Hacohen (B127) 2014; 85
Oliver (B181) 2003; 171
Baumann (B135) 2015; 86
Lyons (B91) 2002; 32
Weissert (B70) 2001; 166
Spadaro (B165) 2016; 3
Ohtani (B54) 2011; 31
Ortega (B83) 2013; 191
Curtis (B85) 2014; 9
Kaneko (B173) 2016; 87
Kakalacheva (B155) 2016; 8
Parker Harp (B95) 2015; 194
Pham-Dinh (B2) 1993; 90
Bettelli (B71) 2003; 197
Bradl (B23) 1996; 6
de Graaf (B75) 2008; 38
Matsumoto (B77) 2009; 128
Selter (B113) 2010; 74
Hoftberger (B145) 2015; 21
Garcia-Vallejo (B12) 2014; 211
Vass (B40) 1992; 32
Pache (B108) 2016; 13
Hyun (B144) 2015; 21
Linares (B15) 2003; 21
Lennon (B177) 2004; 364
Boyle (B6) 2007; 102
Encinas (B64) 1999; 21
Cobo-Calvo (B157) 2016; 22
Misu (B180) 2013; 125
Krishnamoorthy (B10) 2009; 15
Trotter (B36) 1986; 47
Stefferl (B87) 1999; 163
Kim (B148) 2015; 2
Polat (B163) 2016; 137
Konig (B178) 2008; 65
Delarasse (B14) 2003; 112
Amano (B131) 2014; 14
Sepulveda (B161) 2016; 3
Kuhle (B106) 2007; 356
Kitley (B125) 2014; 71
Ramanathan (B159) 2016; 22
Tsuburaya (B133) 2015; 37
Krishnamoorthy (B74) 2006; 116
Yan (B156) 2016; 59
Haanstra (B84) 2013; 8
Mayer (B122) 2013; 191
Jarius (B174) 2016; 13
Wang (B167) 2016; 87
Lassmann (B99) 2017; 133
Burrer (B182) 2007; 170
Fernandez-Carbonell (B152) 2016; 22
19483694 - Nat Med. 2009 Jun;15(6):626-32
24323356 - J Exp Med. 2013 Dec 16;210(13):2921-37
17573820 - J Neurochem. 2007 Sep;102(6):1853-62
19487416 - J Exp Med. 2009 Jun 8;206(6):1303-16
1453482 - J Neurosci Res. 1992 Sep;33(1):177-87
9988264 - Nat Genet. 1999 Feb;21(2):158-60
7684687 - Eur J Immunol. 1993 Jun;23(6):1364-72
8675668 - J Clin Invest. 1995 Dec;96(6):2966-74
26090495 - J Immunol Res. 2015;2015:673503
15589308 - Lancet. 2004 Dec 11-17;364(9451):2106-12
17255324 - Am J Pathol. 2007 Feb;170(2):557-66
2450462 - Am J Pathol. 1988 Mar;130(3):443-54
20033986 - Ann Neurol. 2009 Dec;66(6):833-42
16903876 - J Neurochem. 2006 Sep;98(6):1707-17
22371853 - Arch Neurol. 2012 Jun;69(6):752-6
26869529 - Mult Scler. 2016 Oct;22(12 ):1541-1549
2445777 - J Neuroimmunol. 1987 Dec;17(1):61-9
17121989 - Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18697-702
25121570 - J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72
8144912 - J Immunol. 1994 Mar 15;152(6):3183-8
2765095 - J Autoimmun. 1989 Apr;2(2):115-32
22204662 - J Neuroinflammation. 2011 Dec 28;8:184
25895531 - J Immunol. 2015 Jun 1;194(11):5077-84
26587556 - Neurol Neuroimmunol Neuroinflamm. 2015 Nov 04;2(6):e175
17942684 - Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5
25821844 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89
7537310 - J Immunol. 1995 May 15;154(10):5536-41
26163068 - Mult Scler. 2016 Apr;22(4):470-82
1997396 - Immunology. 1991 Jan;72(1):127-32
9202313 - J Neurochem. 1997 Jul;69(1):214-22
27802824 - J Neuroinflammation. 2016 Nov 1;13(1):282
27766432 - Acta Neuropathol. 2017 Feb;133(2):223-244
17142321 - Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19057-62
23128668 - Mult Scler. 2013 Jun;19(7):941-6
3500978 - J Immunol. 1987 Dec 15;139(12):4016-21
12732654 - J Exp Med. 2003 May 5;197(9):1073-81
22279107 - J Immunol. 2012 Mar 1;188(5):2084-92
2462020 - J Neurochem. 1989 Jan;52(1):296-304
26645082 - J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):897-905
25815356 - Ann Clin Transl Neurol. 2015 Mar;2(3):295-301
23876060 - Immunology. 2013 Dec;140(4):456-64
9739061 - J Clin Invest. 1998 Sep 15;102(6):1265-73
17237795 - Nat Med. 2007 Feb;13(2):211-7
25821843 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e88
26920678 - Sci China Life Sci. 2016 Dec;59(12 ):1270-1281
26869530 - Mult Scler. 2016 Dec;22(14 ):1821-1829
7717689 - Ann Neurol. 1995 Apr;37(4):519-30
22493449 - J Biol Chem. 2012 May 18;287(21):17206-13
26922251 - Brain Dev. 2016 Aug;38(7):690-3
9794370 - J Immunol. 1998 Nov 1;161(9):4480-3
11063818 - J Neuroimmunol. 2000 Nov 1;111(1-2):23-33
24045088 - J Neurol Sci. 2013 Dec 15;335(1-2):221-3
12925695 - J Clin Invest. 2003 Aug;112(4):544-53
27181546 - Intern Med. 2016;55(10 ):1351-4
26347141 - J Cell Biol. 2015 Sep 14;210(6):891-8
16461459 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2280-5
24703097 - J Neuroimmunol. 2014 May 15;270(1-2):98-9
20410464 - Neurology. 2010 May 25;74(21):1711-5
8367453 - Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7990-4
16955141 - J Clin Invest. 2006 Sep;116(9):2393-402
23579868 - Acta Neuropathol. 2013 Jun;125(6):815-27
22914827 - Neurology. 2012 Sep 18;79(12):1273-7
438816 - J Neurochem. 1979 May;32(5):1451-60
19320002 - Exp Neurol. 2009 Apr;216(2):431-8
27244783 - Pediatrics. 2016 May;137(5):null
16955140 - J Clin Invest. 2006 Sep;116(9):2385-92
25364774 - Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40
18379435 - J Neuropathol Exp Neurol. 2008 Apr;67(4):326-40
10443879 - Ann Neurol. 1999 Aug;46(2):144-60
25305252 - Mult Scler. 2015 May;21(6):710-7
14688379 - J Immunol. 2004 Jan 1;172(1):661-8
21251877 - Trends Mol Med. 2011 Mar;17(3):119-25
20573031 - Neuropathology. 2011 Apr;31(2):101-11
25257613 - Mult Scler. 2015 Apr;21(5):656-9
12578856 - Int Immunol. 2003 Feb;15(2):261-8
26957602 - Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3323-8
10384097 - J Immunol. 1999 Jul 1;163(1):40-9
10878388 - J Immunol. 2000 Jul 15;165(2):1093-101
9143251 - J Neuroimmunol. 1997 May;75(1-2):169-73
4179459 - Exp Neurol. 1968 Dec;22(4):545-55
26800711 - J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259
6362005 - Science. 1983 Dec 23;222(4630):1337-9
24582475 - Brain Dev. 2015 Jan;37(1):145-8
11390515 - J Immunol. 2001 Jun 15;166(12):7588-99
20172692 - J Autoimmun. 2010 Aug;35(1):33-44
8864286 - Brain Pathol. 1996 Jul;6(3):303-11
25998291 - Diabetes Care. 2015 Jun;38(6):989-96
26907324 - Viruses. 2016 Feb 12;8(2):null
28331892 - Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335
15259004 - Eur J Immunol. 2004 Aug;34(8):2072-83
25749692 - J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446-8
26516628 - Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
16306341 - Diabetes. 2005 Dec;54 Suppl 2:S52-61
27128728 - Neuropediatrics. 2016 Aug;47(4):245-52
21177754 - Mult Scler. 2011 Mar;17(3):297-302
24133290 - J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):456-61
1695240 - J Neurochem. 1990 Aug;55(2):583-7
19687098 - J Immunol. 2009 Sep 15;183(6):4067-76
26918533 - Dev Med Child Neurol. 2016 Aug;58(8):836-41
8943561 - Int Immunol. 1996 Nov;8(11):1667-74
26668077 - J Neurol. 2016 Feb;263(2):370-9
12853586 - N Engl J Med. 2003 Jul 10;349(2):139-45
25340074 - Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e22
15634682 - J Biol Chem. 2005 Mar 11;280(10):8985-93
26000330 - Ann Clin Transl Neurol. 2015 May;2(5):581-93
26984094 - Intern Med. 2016;55(6):699-702
24610298 - Neuropediatrics. 2014 Jun;45(3):196-9
7688186 - Am J Pathol. 1993 Aug;143(2):555-64
25303101 - PLoS One. 2014 Oct 10;9(10):e110048
12115614 - Eur J Immunol. 2002 Jul;32(7):1939-46
7525700 - J Immunol. 1994 Nov 15;153(10):4349-56
19540601 - J Neuroimmunol. 2009 Aug 18;213(1-2):60-8
25662345 - Mult Scler. 2015 Oct;21(12):1513-20
19001173 - Arch Neurol. 2008 Nov;65(11):1527-32
12817030 - J Immunol. 2003 Jul 1;171(1):455-61
27049558 - J Neuroimmunol. 2016 Apr 15;293:28-33
17251533 - N Engl J Med. 2007 Jan 25;356(4):371-8
23797245 - Nat Rev Neurol. 2013 Aug;9(8):455-61
25506781 - JAMA Neurol. 2015 Feb;72(2):187-93
11739534 - J Immunol. 2001 Dec 15;167(12):7119-25
9804377 - Brain Pathol. 1998 Oct;8(4):681-94
26637427 - Acta Neuropathol Commun. 2015 Dec 04;3:80
8557821 - J Neuroimmunol. 1995 Dec;63(1):17-27
25520558 - Magn Reson Insights. 2014 Nov 09;7:23-31
10556797 - Eur J Immunol. 1999 Nov;29(11):3432-9
11782255 - Immunol Rev. 2001 Oct;183:159-72
27022743 - Acta Neuropathol. 2016 Jul;132(1):43-58
27788675 - J Neuroinflammation. 2016 Sep 26;13(1):279
11169409 - Eur J Immunol. 2000 Dec;30(12):3663-71
20129932 - Brain. 2010 Feb;133(Pt 2):333-48
27306633 - Neurology. 2016 Jul 12;87(2):229-31
16172404 - Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13992-7
7621871 - Eur J Immunol. 1995 Jul;25(7):1951-9
10580814 - J Neuroimmunol. 1999 Nov 1;101(1):61-7
21795651 - Neurology. 2011 Aug 9;77(6):580-8
14624757 - J Autoimmun. 2003 Dec;21(4):339-51
25838512 - BMJ Open. 2015 Apr 02;5(4):e007766
24415568 - Neurology. 2014 Feb 11;82(6):474-81
7737302 - Eur J Immunol. 1995 Apr;25(4):985-93
58035 - J Immunol. 1976 May;116(5):1439-46
23257621 - Mult Scler. 2013 Jul;19(8):1052-9
24700511 - Ann Neurol. 2014 Mar;75(3):411-28
12244307 - Nat Immunol. 2002 Oct;3(10):944-50
27147513 - J Neurol. 2016 Jul;263(7):1349-60
27144216 - Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225
24014878 - J Immunol. 2013 Oct 1;191(7):3594-604
26185777 - Neurol Neuroimmunol Neuroinflamm. 2015 Jul 02;2(4):e131
26498263 - Mult Scler. 2016 Jun;22(7):964-8
27802825 - J Neuroinflammation. 2016 Nov 1;13(1):281
24425068 - JAMA Neurol. 2014 Mar;71(3):276-83
22031325 - Nature. 2011 Oct 26;479(7374):538-41
21146219 - Mol Immunol. 2011 Jun;48(11):1332-7
11024537 - J Neuroimmunol. 2000 Oct 2;110(1-2):83-96
27458601 - Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
15761848 - Eur J Immunol. 2005 Apr;35(4):1311-9
21169067 - Clin Immunol. 2011 Mar;138(3):247-54
21928277 - Eur J Immunol. 2012 Jan;42(1):217-27
26209592 - Mult Scler. 2016 Mar;22(3):312-9
23733879 - J Immunol. 2013 Jul 1;191(1):117-26
25344373 - Mult Scler. 2015 Jun;21(7):866-74
26593750 - Eur J Neurol. 2016 Mar;23 (3):580-7
24685353 - Acta Neuropathol Commun. 2014 Mar 31;2:35
1510359 - Ann Neurol. 1992 Aug;32(2):198-206
22157536 - J Neuroophthalmol. 2012 Jun;32(2):107-10
1385471 - J Neuroimmunol. 1992 Oct;40(2-3):219-24
25434485 - BMC Neurol. 2014 Nov 30;14:224
12843245 - J Neurosci. 2003 Jul 2;23(13):5461-71
12115610 - Eur J Immunol. 2002 Jul;32(7):1905-13
3259787 - Acta Neuropathol. 1988;75(6):566-76
21880773 - J Virol. 2011 Nov;85(21):11038-47
25681455 - Neurology. 2015 Mar 17;84(11):1177-9
12060766 - Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8207-12
19871595 - J Exp Med. 1947 Jan 1;85(1):117-30
25340056 - Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12
9653093 - J Exp Med. 1998 Jul 6;188(1):169-80
1697648 - Nature. 1990 Sep 13;347(6289):151-6
24935259 - J Exp Med. 2014 Jun 30;211(7):1465-83
25798445 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81
9771980 - Autoimmunity. 1998;28(2):109-20
26010364 - Eur J Neurol. 2015 Aug;22(8):1162-8
27793206 - J Neuroinflammation. 2016 Sep 27;13(1):280
2430983 - J Cell Biol. 1986 Dec;103(6 Pt 1):2439-48
12817031 - J Immunol. 2003 Jul 1;171(1):462-8
18050272 - Eur J Immunol. 2008 Jan;38(1):299-308
25889963 - J Neuroinflammation. 2015 Mar 08;12:46
19175799 - Immunology. 2009 Sep;128(1 Suppl):e250-61
23821341 - J Neuroimmune Pharmacol. 2013 Dec;8(5):1251-64
18209026 - J Immunol. 2008 Feb 1;180(3):1326-37
26041801 - Mult Scler. 2016 Feb;22(2):174-84
3734801 - J Neurochem. 1986 Sep;47(3):779-89
References_xml – volume: 79
  start-page: 1273
  year: 2012
  ident: B119
  article-title: Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e31826aac4e
– volume: 210
  start-page: 2921
  year: 2013
  ident: B94
  article-title: MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies
  publication-title: J Exp Med
  doi: 10.1084/jem.20130699
– volume: 2
  start-page: 295
  year: 2015
  ident: B136
  article-title: Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.164
– volume: 19
  start-page: 941
  year: 2013
  ident: B120
  article-title: Acute disseminated encephalomyelitis followed by recurrent or monophasic optic neuritis in pediatric patients
  publication-title: Mult Scler
  doi: 10.1177/1352458512466317
– volume: 8
  start-page: 1251
  year: 2013
  ident: B84
  article-title: Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund’s adjuvant in three non-human primate species
  publication-title: J Neuroimmune Pharmacol
  doi: 10.1007/s11481-013-9487-z
– volume: 2
  start-page: 35
  year: 2014
  ident: B57
  article-title: Neuromyelitis optica MOG-IgG causes reversible lesions in mouse brain
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/2051-5960-2-35
– volume: 293
  start-page: 28
  year: 2016
  ident: B162
  article-title: Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2016.02.004
– volume: 87
  start-page: 1257
  year: 2016
  ident: B173
  article-title: Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2015-312676
– volume: 58
  start-page: 836
  year: 2016
  ident: B170
  article-title: Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies
  publication-title: Dev Med Child Neurol
  doi: 10.1111/dmcn.13090
– volume: 32
  start-page: 1939
  year: 2002
  ident: B96
  article-title: A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(200207)32:7<1939::AID-IMMU1939>3.0.CO;2-S
– volume: 197
  start-page: 1073
  year: 2003
  ident: B71
  article-title: Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis
  publication-title: J Exp Med
  doi: 10.1084/jem.20021603
– volume: 22
  start-page: 545
  year: 1968
  ident: B19
  article-title: The in vitro demyelinating activity of sera from Guinea pigs sensitized with whole CNS and with purified encephalitogen
  publication-title: Exp Neurol
  doi: 10.1016/0014-4886(68)90148-9
– volume: 17
  start-page: 297
  year: 2011
  ident: B114
  article-title: Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children
  publication-title: Mult Scler
  doi: 10.1177/1352458510389220
– volume: 55
  start-page: 1351
  year: 2016
  ident: B151
  article-title: Anti-myelin oligodendrocyte glycoprotein antibodies in a patient with recurrent optic neuritis involving the cerebral white matter and brainstem
  publication-title: Intern Med
  doi: 10.2169/internalmedicine.55.6122
– volume: 38
  start-page: 690
  year: 2016
  ident: B171
  article-title: Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy
  publication-title: Brain Dev
  doi: 10.1016/j.braindev.2016.02.004
– volume: 103
  start-page: 2439
  year: 1986
  ident: B5
  article-title: Immunoelectron microscopic localization of neural cell adhesion molecules (L1, N-CAM, and MAG) and their shared carbohydrate epitope and myelin basic protein in developing sciatic nerve
  publication-title: J Cell Biol
  doi: 10.1083/jcb.103.6.2439
– volume: 6
  start-page: 303
  year: 1996
  ident: B23
  article-title: Animal models of demyelination
  publication-title: Brain Pathol
  doi: 10.1111/j.1750-3639.1996.tb00857.x
– volume: 111
  start-page: 23
  year: 2000
  ident: B66
  article-title: Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement
  publication-title: J Neuroimmunol
  doi: 10.1016/S0165-5728(00)00360-X
– volume: 161
  start-page: 4480
  year: 1998
  ident: B92
  article-title: B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization
  publication-title: J Immunol
  doi: 10.4049/jimmunol.161.9.4480
– volume: 183
  start-page: 159
  year: 2001
  ident: B104
  article-title: Experimental allergic encephalomyelitis in the New World monkey Callithrix jacchus
  publication-title: Immunol Rev
  doi: 10.1034/j.1600-065x.2001.1830113.x
– volume: 22
  start-page: 174
  year: 2016
  ident: B152
  article-title: Clinical and MRI phenotype of children with MOG antibodies
  publication-title: Mult Scler
  doi: 10.1177/1352458515587751
– volume: 103
  start-page: 18697
  year: 2006
  ident: B51
  article-title: Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptors
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0607283103
– volume: 140
  start-page: 456
  year: 2013
  ident: B34
  article-title: Novel pathogenic epitopes of myelin oligodendrocyte glycoprotein induce experimental autoimmune encephalomyelitis in C57BL/6 mice
  publication-title: Immunology
  doi: 10.1111/imm.12155
– volume: 4
  start-page: e335
  year: 2017
  ident: B179
  article-title: ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000335
– volume: 30
  start-page: 3663
  year: 2000
  ident: B68
  article-title: Myelin oligodendrocyte glycoprotein-DNA vaccination induces antibody-mediated autoaggression in experimental autoimmune encephalomyelitis
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(200012)30:12<3663::AID-IMMU3663>3.0.CO;2-7
– volume: 22
  start-page: 1162
  year: 2015
  ident: B107
  article-title: Antibody biomarkers in CNS demyelinating diseases – a long and winding road
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12759
– volume: 98
  start-page: 1707
  year: 2006
  ident: B1
  article-title: Complex alternative splicing of the myelin oligodendrocyte glycoprotein gene is unique to human and non-human primates
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2006.04053.x
– volume: 8
  start-page: 681
  year: 1998
  ident: B63
  article-title: Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology
  publication-title: Brain Pathol
  doi: 10.1111/j.1750-3639.1998.tb00194.x
– volume: 479
  start-page: 538
  year: 2011
  ident: B98
  article-title: Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination
  publication-title: Nature
  doi: 10.1038/nature10554
– volume: 17
  start-page: 119
  year: 2011
  ident: B101
  article-title: EAE: imperfect but useful models of multiple sclerosis
  publication-title: Trends Mol Med
  doi: 10.1016/j.molmed.2010.11.006
– volume: 55
  start-page: 699
  year: 2016
  ident: B150
  article-title: An adult case of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated multiphasic acute disseminated encephalomyelitis at 33-year intervals
  publication-title: Intern Med
  doi: 10.2169/internalmedicine.55.5727
– volume: 38
  start-page: 989
  year: 2015
  ident: B189
  article-title: Predicting type 1 diabetes using biomarkers
  publication-title: Diabetes Care
  doi: 10.2337/dc15-0101
– volume: 112
  start-page: 544
  year: 2003
  ident: B14
  article-title: Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice
  publication-title: J Clin Invest
  doi: 10.1172/JCI15861
– volume: 47
  start-page: 779
  year: 1986
  ident: B36
  article-title: Opsonization with antimyelin antibody increases the uptake and intracellular metabolism of myelin in inflammatory macrophages
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1986.tb00679.x
– volume: 191
  start-page: 117
  year: 2013
  ident: B83
  article-title: The disease-ameliorating function of autoregulatory CD8 T cells is mediated by targeting of encephalitogenic CD4 T cells in experimental autoimmune encephalomyelitis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1300452
– volume: 8
  start-page: E51
  year: 2016
  ident: B155
  article-title: Infectious mononucleosis triggers generation of IgG auto-antibodies against native myelin oligodendrocyte glycoprotein
  publication-title: Viruses
  doi: 10.3390/v8020051
– volume: 3
  start-page: 944
  year: 2002
  ident: B93
  article-title: B cells regulate autoimmunity by provision of IL-10
  publication-title: Nat Immunol
  doi: 10.1038/ni833
– volume: 77
  start-page: 580
  year: 2011
  ident: B116
  article-title: Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e318228c0b1
– volume: 1
  start-page: e40
  year: 2014
  ident: B130
  article-title: Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000040
– volume: 116
  start-page: 2393
  year: 2006
  ident: B97
  article-title: Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice
  publication-title: J Clin Invest
  doi: 10.1172/JCI28334
– volume: 63
  start-page: 17
  year: 1995
  ident: B24
  article-title: The N-terminal domain of the myelin oligodendrocyte glycoprotein (MOG) induces acute demyelinating experimental autoimmune encephalomyelitis in the Lewis rat
  publication-title: J Neuroimmunol
  doi: 10.1016/0165-5728(95)00124-7
– volume: 22
  start-page: 1541
  year: 2016
  ident: B172
  article-title: Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case
  publication-title: Mult Scler
  doi: 10.1177/1352458515622986
– volume: 356
  start-page: 371
  year: 2007
  ident: B106
  article-title: Lack of association between antimyelin antibodies and progression to multiple sclerosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa063602
– volume: 2
  start-page: e175
  year: 2015
  ident: B149
  article-title: Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000175
– volume: 22
  start-page: 312
  year: 2016
  ident: B157
  article-title: Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications
  publication-title: Mult Scler
  doi: 10.1177/1352458515591071
– volume: 14
  start-page: 224
  year: 2014
  ident: B131
  article-title: Influenza-associated MOG antibody-positive longitudinally extensive transverse myelitis: a case report
  publication-title: BMC Neurol
  doi: 10.1186/s12883-014-0224-x
– volume: 213
  start-page: 60
  year: 2009
  ident: B79
  article-title: Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2009.05.017
– volume: 15
  start-page: 626
  year: 2009
  ident: B10
  article-title: Myelin-specific T cells also recognize neuronal autoantigen in a transgenic mouse model of multiple sclerosis
  publication-title: Nat Med
  doi: 10.1038/nm.1975
– volume: 35
  start-page: 1311
  year: 2005
  ident: B73
  article-title: Native myelin oligodendrocyte glycoprotein promotes severe chronic neurological disease and demyelination in Biozzi ABH mice
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200425842
– volume: 72
  start-page: 187
  year: 2015
  ident: B134
  article-title: Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor alpha1 subunit in patients with isolated optic neuritis
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2014.3602
– volume: 125
  start-page: 815
  year: 2013
  ident: B180
  article-title: Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-013-1116-7
– volume: 25
  start-page: 985
  year: 1995
  ident: B31
  article-title: Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830250419
– volume: 133
  start-page: 223
  year: 2017
  ident: B99
  article-title: Multiple sclerosis: experimental models and reality
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-016-1631-4
– volume: 96
  start-page: 2966
  year: 1995
  ident: B43
  article-title: Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate
  publication-title: J Clin Invest
  doi: 10.1172/JCI118368
– volume: 9
  start-page: 455
  year: 2013
  ident: B184
  article-title: The spectrum of MOG autoantibody-associated demyelinating diseases
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2013.118
– volume: 31
  start-page: 101
  year: 2011
  ident: B54
  article-title: Autoantibodies recognizing native MOG are closely associated with active demyelination but not with neuroinflammation in chronic EAE
  publication-title: Neuropathology
  doi: 10.1111/j.1440-1789.2010.01131.x
– volume: 35
  start-page: 33
  year: 2010
  ident: B80
  article-title: Immune regulatory CNS-reactive CD8+T cells in experimental autoimmune encephalomyelitis
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2010.01.003
– volume: 75
  start-page: 169
  year: 1997
  ident: B60
  article-title: Induction of EAE in mice with recombinant human MOG, and treatment of EAE with a MOG peptide
  publication-title: J Neuroimmunol
  doi: 10.1016/S0165-5728(97)00019-2
– volume: 2015
  start-page: 673503
  year: 2015
  ident: B132
  article-title: Decreased frequency of circulating myelin oligodendrocyte glycoprotein B lymphocytes in patients with relapsing-remitting multiple sclerosis
  publication-title: J Immunol Res
  doi: 10.1155/2015/673503
– volume: 206
  start-page: 1303
  year: 2009
  ident: B78
  article-title: Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells
  publication-title: J Exp Med
  doi: 10.1084/jem.20090299
– volume: 188
  start-page: 169
  year: 1998
  ident: B89
  article-title: B lymphocytes producing demyelinating autoantibodies: development and function in gene-targeted transgenic mice
  publication-title: J Exp Med
  doi: 10.1084/jem.188.1.169
– volume: 13
  start-page: 282
  year: 2016
  ident: B108
  article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-016-0720-6
– volume: 85
  start-page: 456
  year: 2014
  ident: B127
  article-title: Autoantibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2013-306411
– volume: 270
  start-page: 98
  year: 2014
  ident: B128
  article-title: Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system
  publication-title: J Neuroimmunol
  doi: 10.1016/j.jneuroim.2014.03.001
– volume: 47
  start-page: 245
  year: 2016
  ident: B168
  article-title: Myelin oligodendrocyte glycoprotein-associated pediatric central nervous system demyelination: clinical course, neuroimaging findings, and response to therapy
  publication-title: Neuropediatrics
  doi: 10.1055/s-0036-1583184
– volume: 23
  start-page: 5461
  year: 2003
  ident: B48
  article-title: Antibody cross-linking of myelin oligodendrocyte glycoprotein leads to its rapid repartitioning into detergent-insoluble fractions, and altered protein phosphorylation and cell morphology
  publication-title: J Neurosci
  doi: 10.1523/JNEUROSCI.23-13-05461.2003
– volume: 2
  start-page: 115
  year: 1989
  ident: B16
  article-title: Chronic experimental autoimmune encephalomyelitis in the Guinea pig. Presence of anti-M2 antibodies in central nervous system tissue and the possible role of M2 autoantigen in the induction of the disease
  publication-title: J Autoimmun
  doi: 10.1016/0896-8411(89)90149-2
– volume: 32
  start-page: 1905
  year: 2002
  ident: B91
  article-title: Critical role of antigen-specific antibody in experimental autoimmune encephalomyelitis induced by recombinant myelin oligodendrocyte glycoprotein
  publication-title: Eur J Immunol
  doi: 10.1002/1521-4141(200207)32:7<1905::AID-IMMU1905>3.0.CO;2-L
– volume: 263
  start-page: 370
  year: 2016
  ident: B153
  article-title: Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up
  publication-title: J Neurol
  doi: 10.1007/s00415-015-7983-1
– volume: 116
  start-page: 2385
  year: 2006
  ident: B74
  article-title: Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation
  publication-title: J Clin Invest
  doi: 10.1172/JCI28330
– volume: 84
  start-page: 1177
  year: 2015
  ident: B139
  article-title: Anti-MOG antibodies with longitudinally extensive transverse myelitis preceded by CLIPPERS
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000001370
– volume: 17
  start-page: 61
  year: 1987
  ident: B17
  article-title: Antibody responses in chronic relapsing experimental allergic encephalomyelitis: correlation of serum demyelinating activity with antibody titre to the myelin/oligodendrocyte glycoprotein (MOG)
  publication-title: J Neuroimmunol
  doi: 10.1016/0165-5728(87)90031-2
– volume: 32
  start-page: 1451
  year: 1979
  ident: B21
  article-title: Studies on autoimmune encephalomyelitis in the Guinea pig – III. A comparative study of two autoantigens of central nervous system myelin
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1979.tb11084.x
– volume: 69
  start-page: 214
  year: 1997
  ident: B46
  article-title: Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin
  publication-title: J Neurochem
  doi: 10.1046/j.1471-4159.1997.69010214.x
– volume: 2
  start-page: e163
  year: 2015
  ident: B148
  article-title: Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000163
– volume: 23
  start-page: 580
  year: 2016
  ident: B158
  article-title: Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands
  publication-title: Eur J Neurol
  doi: 10.1111/ene.12898
– volume: 66
  start-page: 833
  year: 2009
  ident: B112
  article-title: Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease
  publication-title: Ann Neurol
  doi: 10.1002/ana.21916
– volume: 165
  start-page: 1093
  year: 2000
  ident: B69
  article-title: Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule
  publication-title: J Immunol
  doi: 10.4049/jimmunol.165.2.1093
– volume: 171
  start-page: 455
  year: 2003
  ident: B28
  article-title: Selective unresponsiveness to conformational B cell epitopes of the myelin oligodendrocyte glycoprotein in H-2b mice
  publication-title: J Immunol
  doi: 10.4049/jimmunol.171.1.455
– volume: 1
  start-page: e12
  year: 2014
  ident: B56
  article-title: Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000012
– volume: 7
  start-page: 23
  year: 2014
  ident: B86
  article-title: Damage to the optic chiasm in myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis mice
  publication-title: Magn Reson Insights
  doi: 10.4137/MRI.S19750
– volume: 364
  start-page: 2106
  year: 2004
  ident: B177
  article-title: A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(04)17551-X
– volume: 2
  start-page: e81
  year: 2015
  ident: B138
  article-title: Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000081
– volume: 59
  start-page: 1270
  year: 2016
  ident: B156
  article-title: Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD
  publication-title: Sci China Life Sci
  doi: 10.1007/s11427-015-4997-y
– volume: 25
  start-page: 1951
  year: 1995
  ident: B32
  article-title: A myelin oligodendrocyte glycoprotein peptide induces typical chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor V beta expression of encephalitogenic T cells
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830250723
– volume: 137
  start-page: e20151958
  year: 2016
  ident: B163
  article-title: Myelin oligodendrocyte glycoprotein antibody persistency in a steroid-dependent ADEM case
  publication-title: Pediatrics
  doi: 10.1542/peds.2015-1958
– volume: 13
  start-page: 281
  year: 2016
  ident: B176
  article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement – frequency, presentation and outcome
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-016-0717-1
– volume: 55
  start-page: 583
  year: 1990
  ident: B38
  article-title: Demyelination induced in aggregating brain cell cultures by a monoclonal antibody against myelin/oligodendrocyte glycoprotein
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1990.tb04173.x
– volume: 188
  start-page: 2084
  year: 2012
  ident: B81
  article-title: A transgenic model of central nervous system autoimmunity mediated by CD4+ and CD8+ T and B cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1102186
– volume: 23
  start-page: 1364
  year: 1993
  ident: B33
  article-title: T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system
  publication-title: Eur J Immunol
  doi: 10.1002/eji.1830230627
– volume: 2
  start-page: 581
  year: 2015
  ident: B102
  article-title: The primate autoimmune encephalomyelitis model; a bridge between mouse and man
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.194
– volume: 2
  start-page: e88
  year: 2015
  ident: B140
  article-title: A 41-year-old woman with acute weakness and encephalopathy associated with MOG antibodies
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000088
– volume: 87
  start-page: 229
  year: 2016
  ident: B167
  article-title: Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002844
– volume: 13
  start-page: 280
  year: 2016
  ident: B175
  article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-016-0718-0
– volume: 38
  start-page: 299
  year: 2008
  ident: B75
  article-title: Characterization of the encephalitogenic immune response in a model of multiple sclerosis
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200737475
– volume: 48
  start-page: 1332
  year: 2011
  ident: B29
  article-title: B cells in spontaneous autoimmune diseases of the central nervous system
  publication-title: Mol Immunol
  doi: 10.1016/j.molimm.2010.10.025
– volume: 85
  start-page: 117
  year: 1947
  ident: B18
  article-title: The rapid production of acute disseminated encephalomyelitis in rhesus monkeys by injection of heterologous and homologous brain tissue with adjuvants
  publication-title: J Exp Med
  doi: 10.1084/jem.85.1.117
– volume: 130
  start-page: 443
  year: 1988
  ident: B4
  article-title: Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein
  publication-title: Am J Pathol
– volume: 71
  start-page: 276
  year: 2014
  ident: B125
  article-title: Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study
  publication-title: JAMA Neurol
  doi: 10.1001/jamaneurol.2013.5857
– volume: 347
  start-page: 151
  year: 1990
  ident: B186
  article-title: Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase
  publication-title: Nature
  doi: 10.1038/347151a0
– volume: 22
  start-page: 1821
  year: 2016
  ident: B154
  article-title: Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases
  publication-title: Mult Scler
  doi: 10.1177/1352458516631038
– volume: 85
  start-page: 11038
  year: 2011
  ident: B11
  article-title: Identification of the myelin oligodendrocyte glycoprotein as a cellular receptor for rubella virus
  publication-title: J Virol
  doi: 10.1128/JVI.05398-11
– volume: 211
  start-page: 1465
  year: 2014
  ident: B12
  article-title: CNS myelin induces regulatory functions of DC-SIGN-expressing, antigen-presenting cells via cognate interaction with MOG
  publication-title: J Exp Med
  doi: 10.1084/jem.20122192
– volume: 87
  start-page: 897
  year: 2016
  ident: B169
  article-title: Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2015-311743
– volume: 37
  start-page: 519
  year: 1995
  ident: B103
  article-title: Active and passively induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis
  publication-title: Ann Neurol
  doi: 10.1002/ana.410370415
– volume: 3
  start-page: e257
  year: 2016
  ident: B165
  article-title: Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000257
– volume: 180
  start-page: 1326
  year: 2008
  ident: B76
  article-title: Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.180.3.1326
– volume: 86
  start-page: 265
  year: 2015
  ident: B135
  article-title: Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2014-308346
– volume: 99
  start-page: 8207
  year: 2002
  ident: B25
  article-title: Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.122092499
– volume: 113
  start-page: 3323
  year: 2016
  ident: B58
  article-title: Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1519608113
– volume: 13
  start-page: 211
  year: 2007
  ident: B110
  article-title: Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
  publication-title: Nat Med
  doi: 10.1038/nm1488
– volume: 75
  start-page: 566
  year: 1988
  ident: B22
  article-title: Experimental allergic encephalomyelitis: the balance between encephalitogenic T lymphocytes and demyelinating antibodies determines size and structure of demyelinated lesions
  publication-title: Acta Neuropathol
  doi: 10.1007/BF00686201
– volume: 40
  start-page: 219
  year: 1992
  ident: B41
  article-title: Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody
  publication-title: J Neuroimmunol
  doi: 10.1016/0165-5728(92)90136-9
– volume: 28
  start-page: 109
  year: 1998
  ident: B61
  article-title: Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein
  publication-title: Autoimmunity
  doi: 10.3109/08916939809003872
– volume: 46
  start-page: 144
  year: 1999
  ident: B65
  article-title: Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation
  publication-title: Ann Neurol
  doi: 10.1002/1531-8249(199908)46:2<144::AID-ANA3>3.0.CO;2-K
– volume: 52
  start-page: 296
  year: 1989
  ident: B3
  article-title: Differential ultrastructural localization of myelin basic protein, myelin/oligodendroglial glycoprotein, and 2′,3′-cyclic nucleotide 3′-phosphodiesterase in the CNS of adult rats
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.1989.tb10930.x
– volume: 167
  start-page: 7119
  year: 2001
  ident: B88
  article-title: T cell epitopes of human myelin oligodendrocyte glycoprotein identified in HLA-DR4 (DRB1*0401) transgenic mice are encephalitogenic and are presented by human B cells
  publication-title: J Immunol
  doi: 10.4049/jimmunol.167.12.7119
– volume: 170
  start-page: 557
  year: 2007
  ident: B182
  article-title: Exacerbated pathology of viral encephalitis in mice with central nervous system-specific autoantibodies
  publication-title: Am J Pathol
  doi: 10.2353/ajpath.2007.060893
– volume: 45
  start-page: 196
  year: 2014
  ident: B129
  article-title: Persistent presence of the anti-myelin oligodendrocyte glycoprotein autoantibody in a pediatric case of acute disseminated encephalomyelitis followed by optic neuritis
  publication-title: Neuropediatrics
  doi: 10.1055/s-0034-1371179
– volume: 8
  start-page: 1667
  year: 1996
  ident: B45
  article-title: Antibody response in Lewis rats injected with myelin oligodendrocyte glycoprotein derived peptides
  publication-title: Int Immunol
  doi: 10.1093/intimm/8.11.1667
– volume: 32
  start-page: 107
  year: 2012
  ident: B117
  article-title: Relationship between NMO-antibody and anti-MOG antibody in optic neuritis
  publication-title: J Neuroophthalmol
  doi: 10.1097/WNO.0b013e31823c9b6c
– volume: 13
  start-page: 279
  year: 2016
  ident: B174
  article-title: MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-016-0719-z
– volume: 191
  start-page: 3594
  year: 2013
  ident: B122
  article-title: Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1301296
– volume: 34
  start-page: 2072
  year: 2004
  ident: B49
  article-title: Frontline: epitope recognition on the myelin/oligodendrocyte glycoprotein differentially influences disease phenotype and antibody effector functions in autoimmune demyelination
  publication-title: Eur J Immunol
  doi: 10.1002/eji.200425050
– volume: 103
  start-page: 2280
  year: 2006
  ident: B109
  article-title: Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0510672103
– volume: 166
  start-page: 7588
  year: 2001
  ident: B70
  article-title: MHC class II-regulated central nervous system autoaggression and T cell responses in peripheral lymphoid tissues are dissociated in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.166.12.7588
– volume: 280
  start-page: 8985
  year: 2005
  ident: B7
  article-title: Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M413174200
– volume: 3
  start-page: e225
  year: 2016
  ident: B161
  article-title: Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000225
– volume: 21
  start-page: 158
  year: 1999
  ident: B64
  article-title: QTL influencing autoimmune diabetes and encephalomyelitis map to a 0.15-cM region containing Il2
  publication-title: Nat Genet
  doi: 10.1038/5941
– volume: 12
  start-page: 46
  year: 2015
  ident: B137
  article-title: Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
  publication-title: J Neuroinflammation
  doi: 10.1186/s12974-015-0256-1
– volume: 1
  start-page: e22
  year: 2014
  ident: B35
  article-title: Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000022
– volume: 349
  start-page: 139
  year: 2003
  ident: B105
  article-title: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa022328
– volume: 22
  start-page: 470
  year: 2016
  ident: B159
  article-title: Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis
  publication-title: Mult Scler
  doi: 10.1177/1352458515593406
– volume: 21
  start-page: 656
  year: 2015
  ident: B142
  article-title: Severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody
  publication-title: Mult Scler
  doi: 10.1177/1352458514551455
– volume: 102
  start-page: 1265
  year: 1998
  ident: B62
  article-title: MHC haplotype-dependent regulation of MOG-induced EAE in rats
  publication-title: J Clin Invest
  doi: 10.1172/JCI3022
– volume: 128
  start-page: e250
  year: 2009
  ident: B77
  article-title: Role of pathogenic T cells and autoantibodies in relapse and progression of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in LEW.1AV1 rats
  publication-title: Immunology
  doi: 10.1111/j.1365-2567.2008.02955.x
– volume: 103
  start-page: 19057
  year: 2006
  ident: B50
  article-title: Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0607242103
– volume: 21
  start-page: 710
  year: 2015
  ident: B144
  article-title: Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis
  publication-title: Mult Scler
  doi: 10.1177/1352458514551454
– volume: 5
  start-page: e007766
  year: 2015
  ident: B143
  article-title: Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2015-007766
– volume: 33
  start-page: 177
  year: 1992
  ident: B8
  article-title: Myelin/oligodendrocyte glycoprotein is a unique member of the immunoglobulin superfamily
  publication-title: J Neurosci Res
  doi: 10.1002/jnr.490330123
– volume: 9
  start-page: e110048
  year: 2014
  ident: B85
  article-title: The extracellular domain of myelin oligodendrocyte glycoprotein elicits atypical experimental autoimmune encephalomyelitis in rat and macaque species
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0110048
– volume: 22
  start-page: 964
  year: 2016
  ident: B164
  article-title: The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients
  publication-title: Mult Scler
  doi: 10.1177/1352458515614093
– volume: 163
  start-page: 40
  year: 1999
  ident: B87
  article-title: Myelin oligodendrocyte glycoprotein induces experimental autoimmune encephalomyelitis in the “resistant” brown Norway rat: disease susceptibility is determined by MHC and MHC-linked effects on the B cell response
  publication-title: J Immunol
  doi: 10.4049/jimmunol.163.1.40
– volume: 183
  start-page: 4067
  year: 2009
  ident: B111
  article-title: Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.0801888
– volume: 87
  start-page: 446
  year: 2016
  ident: B160
  article-title: MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study
  publication-title: J Neurol Neurosurg Psychiatry
  doi: 10.1136/jnnp-2014-310206
– volume: 15
  start-page: 261
  year: 2003
  ident: B72
  article-title: Encephalitogenic activity of truncated myelin oligodendrocyte glycoprotein (MOG) peptides and their recognition by CD8+ MOG-specific T cells on oligomeric MHC class I molecules
  publication-title: Int Immunol
  doi: 10.1093/intimm/dxg023
– volume: 82
  start-page: 474
  year: 2014
  ident: B124
  article-title: Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000000101
– volume: 67
  start-page: 326
  year: 2008
  ident: B52
  article-title: Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets
  publication-title: J Neuropathol Exp Neurol
  doi: 10.1097/NEN.0b013e31816a6851
– volume: 21
  start-page: 339
  year: 2003
  ident: B15
  article-title: The magnitude and encephalogenic potential of autoimmune response to MOG is enhanced in MOG deficient mice
  publication-title: J Autoimmun
  doi: 10.1016/j.jaut.2003.09.001
– volume: 21
  start-page: 866
  year: 2015
  ident: B145
  article-title: Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease
  publication-title: Mult Scler
  doi: 10.1177/1352458514555785
– volume: 65
  start-page: 1527
  year: 2008
  ident: B178
  article-title: Persistence of immunopathological and radiological traits in multiple sclerosis
  publication-title: Arch Neurol
  doi: 10.1001/archneur.65.11.1527
– volume: 110
  start-page: 83
  year: 2000
  ident: B67
  article-title: Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes
  publication-title: J Neuroimmunol
  doi: 10.1016/S0165-5728(00)00306-4
– volume: 29
  start-page: 3432
  year: 1999
  ident: B90
  article-title: B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide
  publication-title: Eur J Immunol
  doi: 10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2
– volume: 69
  start-page: 752
  year: 2012
  ident: B118
  article-title: Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis
  publication-title: Arch Neurol
  doi: 10.1001/archneurol.2011.2956
– volume: 194
  start-page: 5077
  year: 2015
  ident: B95
  article-title: B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.1402236
– volume: 37
  start-page: 145
  year: 2015
  ident: B133
  article-title: Anti-myelin oligodendrocyte glycoprotein (MOG) antibodies in a Japanese boy with recurrent optic neuritis
  publication-title: Brain Dev
  doi: 10.1016/j.braindev.2014.02.002
– volume: 132
  start-page: 43
  year: 2016
  ident: B59
  article-title: Myelin-reactive antibodies initiate T cell-mediated CNS autoimmune disease by opsonization of endogenous antigen
  publication-title: Acta Neuropathol
  doi: 10.1007/s00401-016-1559-8
– volume: 8
  start-page: 184
  year: 2011
  ident: B55
  article-title: Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders
  publication-title: J Neuroinflammation
  doi: 10.1186/1742-2094-8-184
– volume: 335
  start-page: 221
  year: 2013
  ident: B123
  article-title: Glycine receptor and myelin oligodendrocyte glycoprotein antibodies in Turkish patients with neuromyelitis optica
  publication-title: J Neurol Sci
  doi: 10.1016/j.jns.2013.08.034
– volume: 21
  start-page: 1513
  year: 2015
  ident: B147
  article-title: Anti-MOG antibodies plead against MS diagnosis in an acquired demyelinating syndromes cohort
  publication-title: Mult Scler
  doi: 10.1177/1352458514566666
– volume: 143
  start-page: 555
  year: 1993
  ident: B42
  article-title: The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement
  publication-title: Am J Pathol
– volume: 102
  start-page: 1853
  year: 2007
  ident: B6
  article-title: Splice variation in the cytoplasmic domains of myelin oligodendrocyte glycoprotein affects its cellular localisation and transport
  publication-title: J Neurochem
  doi: 10.1111/j.1471-4159.2007.04687.x
– volume: 216
  start-page: 431
  year: 2009
  ident: B53
  article-title: Live imaging of remyelination after antibody-mediated demyelination in an ex-vivo model for immune mediated CNS damage
  publication-title: Exp Neurol
  doi: 10.1016/j.expneurol.2008.12.027
– volume: 222
  start-page: 1337
  year: 1983
  ident: B185
  article-title: Insulin antibodies in insulin-dependent diabetics before insulin treatment
  publication-title: Science
  doi: 10.1126/science.6362005
– volume: 116
  start-page: 1439
  year: 1976
  ident: B20
  article-title: Studies on autoimmune encephalomyelitis in the Guinea pig. II. An in vitro investigation on the nature, properties, and specificity of the serum-demyelinating factor
  publication-title: J Immunol
  doi: 10.4049/jimmunol.116.5.1439
– volume: 210
  start-page: 891
  year: 2015
  ident: B13
  article-title: The myelin oligodendrocyte glycoprotein directly binds nerve growth factor to modulate central axon circuitry
  publication-title: J Cell Biol
  doi: 10.1083/jcb.201504106
– volume: 19
  start-page: 1052
  year: 2013
  ident: B121
  article-title: Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica
  publication-title: Mult Scler
  doi: 10.1177/1352458512470310
– volume: 2
  start-page: e131
  year: 2015
  ident: B146
  article-title: Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000131
– volume: 152
  start-page: 3183
  year: 1994
  ident: B187
  article-title: Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases
  publication-title: J Immunol
  doi: 10.4049/jimmunol.152.6.3183
– volume: 72
  start-page: 127
  year: 1991
  ident: B39
  article-title: Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies
  publication-title: Immunology
– volume: 171
  start-page: 462
  year: 2003
  ident: B181
  article-title: Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice
  publication-title: J Immunol
  doi: 10.4049/jimmunol.171.9.4934
– volume: 133
  start-page: 333
  year: 2010
  ident: B183
  article-title: Perivenous demyelination: association with clinically defined acute disseminated encephalomyelitis and comparison with pathologically confirmed multiple sclerosis
  publication-title: Brain
  doi: 10.1093/brain/awp321
– volume: 32
  start-page: 198
  year: 1992
  ident: B40
  article-title: Interferon-gamma potentiates antibody-mediated demyelination in vivo
  publication-title: Ann Neurol
  doi: 10.1002/ana.410320212
– volume: 138
  start-page: 247
  year: 2011
  ident: B115
  article-title: Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases
  publication-title: Clin Immunol
  doi: 10.1016/j.clim.2010.11.013
– volume: 263
  start-page: 1349
  year: 2016
  ident: B166
  article-title: Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes
  publication-title: J Neurol
  doi: 10.1007/s00415-016-8147-7
– volume: 104
  start-page: 17040
  year: 2007
  ident: B188
  article-title: The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0705894104
– volume: 154
  start-page: 5536
  year: 1995
  ident: B44
  article-title: Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.154.10.5536
– volume: 153
  start-page: 4349
  year: 1994
  ident: B30
  article-title: Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice
  publication-title: J Immunol
  doi: 10.4049/jimmunol.153.10.4349
– volume: 3
  start-page: 80
  year: 2015
  ident: B100
  article-title: Autoimmune encephalitis in humans: how closely does it reflect multiple sclerosis?
  publication-title: Acta Neuropathol Commun
  doi: 10.1186/s40478-015-0260-9
– volume: 102
  start-page: 13992
  year: 2005
  ident: B26
  article-title: Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0504979102
– volume: 101
  start-page: 61
  year: 1999
  ident: B47
  article-title: The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages
  publication-title: J Neuroimmunol
  doi: 10.1016/S0165-5728(99)00133-2
– volume: 42
  start-page: 217
  year: 2012
  ident: B82
  article-title: Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant
  publication-title: Eur J Immunol
  doi: 10.1002/eji.201141863
– volume: 2
  start-page: e89
  year: 2015
  ident: B141
  article-title: MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
  publication-title: Neurol Neuroimmunol Neuroinflamm
  doi: 10.1212/NXI.0000000000000089
– volume: 90
  start-page: 7990
  year: 1993
  ident: B2
  article-title: Myelin/oligodendrocyte glycoprotein is a member of a subset of the immunoglobulin superfamily encoded within the major histocompatibility complex
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.90.17.7990
– volume: 139
  start-page: 4016
  year: 1987
  ident: B37
  article-title: A monoclonal antibody against a myelin oligodendrocyte glycoprotein induces relapses and demyelination in central nervous system autoimmune disease
  publication-title: J Immunol
  doi: 10.4049/jimmunol.139.12.4016
– volume: 54
  start-page: S52
  year: 2005
  ident: B190
  article-title: Autoantibodies in diabetes
  publication-title: Diabetes
  doi: 10.2337/diabetes.54.suppl_2.S52
– volume: 287
  start-page: 17206
  year: 2012
  ident: B27
  article-title: Autoantigen conformation influences both B- and T-cell responses and encephalitogenicity
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M111.304246
– volume: 74
  start-page: 1711
  year: 2010
  ident: B113
  article-title: Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases
  publication-title: Neurology
  doi: 10.1212/WNL.0b013e3181e04096
– volume: 172
  start-page: 661
  year: 2004
  ident: B9
  article-title: Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis
  publication-title: J Immunol
  doi: 10.4049/jimmunol.172.1.661
– volume: 75
  start-page: 411
  year: 2014
  ident: B126
  article-title: Overlapping demyelinating syndromes and anti-N-methyl-d-aspartate receptor encephalitis
  publication-title: Ann Neurol
  doi: 10.1002/ana.24117
– reference: 12115614 - Eur J Immunol. 2002 Jul;32(7):1939-46
– reference: 24582475 - Brain Dev. 2015 Jan;37(1):145-8
– reference: 9143251 - J Neuroimmunol. 1997 May;75(1-2):169-73
– reference: 19483694 - Nat Med. 2009 Jun;15(6):626-32
– reference: 26920678 - Sci China Life Sci. 2016 Dec;59(12 ):1270-1281
– reference: 27244783 - Pediatrics. 2016 May;137(5):null
– reference: 21251877 - Trends Mol Med. 2011 Mar;17(3):119-25
– reference: 25821843 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e88
– reference: 3259787 - Acta Neuropathol. 1988;75(6):566-76
– reference: 19687098 - J Immunol. 2009 Sep 15;183(6):4067-76
– reference: 9988264 - Nat Genet. 1999 Feb;21(2):158-60
– reference: 15761848 - Eur J Immunol. 2005 Apr;35(4):1311-9
– reference: 6362005 - Science. 1983 Dec 23;222(4630):1337-9
– reference: 25998291 - Diabetes Care. 2015 Jun;38(6):989-96
– reference: 26010364 - Eur J Neurol. 2015 Aug;22(8):1162-8
– reference: 22371853 - Arch Neurol. 2012 Jun;69(6):752-6
– reference: 10878388 - J Immunol. 2000 Jul 15;165(2):1093-101
– reference: 24415568 - Neurology. 2014 Feb 11;82(6):474-81
– reference: 23797245 - Nat Rev Neurol. 2013 Aug;9(8):455-61
– reference: 1697648 - Nature. 1990 Sep 13;347(6289):151-6
– reference: 8557821 - J Neuroimmunol. 1995 Dec;63(1):17-27
– reference: 2765095 - J Autoimmun. 1989 Apr;2(2):115-32
– reference: 7684687 - Eur J Immunol. 1993 Jun;23(6):1364-72
– reference: 22031325 - Nature. 2011 Oct 26;479(7374):538-41
– reference: 16903876 - J Neurochem. 2006 Sep;98(6):1707-17
– reference: 7737302 - Eur J Immunol. 1995 Apr;25(4):985-93
– reference: 25303101 - PLoS One. 2014 Oct 10;9(10):e110048
– reference: 26090495 - J Immunol Res. 2015;2015:673503
– reference: 25889963 - J Neuroinflammation. 2015 Mar 08;12:46
– reference: 7537310 - J Immunol. 1995 May 15;154(10):5536-41
– reference: 25340056 - Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12
– reference: 1453482 - J Neurosci Res. 1992 Sep;33(1):177-87
– reference: 1510359 - Ann Neurol. 1992 Aug;32(2):198-206
– reference: 17942684 - Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17040-5
– reference: 18379435 - J Neuropathol Exp Neurol. 2008 Apr;67(4):326-40
– reference: 20172692 - J Autoimmun. 2010 Aug;35(1):33-44
– reference: 25340074 - Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e22
– reference: 25506781 - JAMA Neurol. 2015 Feb;72(2):187-93
– reference: 25257613 - Mult Scler. 2015 Apr;21(5):656-9
– reference: 19871595 - J Exp Med. 1947 Jan 1;85(1):117-30
– reference: 25895531 - J Immunol. 2015 Jun 1;194(11):5077-84
– reference: 7621871 - Eur J Immunol. 1995 Jul;25(7):1951-9
– reference: 14624757 - J Autoimmun. 2003 Dec;21(4):339-51
– reference: 22157536 - J Neuroophthalmol. 2012 Jun;32(2):107-10
– reference: 7717689 - Ann Neurol. 1995 Apr;37(4):519-30
– reference: 9771980 - Autoimmunity. 1998;28(2):109-20
– reference: 26668077 - J Neurol. 2016 Feb;263(2):370-9
– reference: 24703097 - J Neuroimmunol. 2014 May 15;270(1-2):98-9
– reference: 27458601 - Neurol Neuroimmunol Neuroinflamm. 2016 Jun 30;3(5):e257
– reference: 26800711 - J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1257-1259
– reference: 25838512 - BMJ Open. 2015 Apr 02;5(4):e007766
– reference: 7525700 - J Immunol. 1994 Nov 15;153(10):4349-56
– reference: 24425068 - JAMA Neurol. 2014 Mar;71(3):276-83
– reference: 1385471 - J Neuroimmunol. 1992 Oct;40(2-3):219-24
– reference: 9794370 - J Immunol. 1998 Nov 1;161(9):4480-3
– reference: 12853586 - N Engl J Med. 2003 Jul 10;349(2):139-45
– reference: 26984094 - Intern Med. 2016;55(6):699-702
– reference: 14688379 - J Immunol. 2004 Jan 1;172(1):661-8
– reference: 17251533 - N Engl J Med. 2007 Jan 25;356(4):371-8
– reference: 3500978 - J Immunol. 1987 Dec 15;139(12):4016-21
– reference: 8144912 - J Immunol. 1994 Mar 15;152(6):3183-8
– reference: 25344373 - Mult Scler. 2015 Jun;21(7):866-74
– reference: 25305252 - Mult Scler. 2015 May;21(6):710-7
– reference: 26645082 - J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):897-905
– reference: 19320002 - Exp Neurol. 2009 Apr;216(2):431-8
– reference: 27049558 - J Neuroimmunol. 2016 Apr 15;293:28-33
– reference: 11739534 - J Immunol. 2001 Dec 15;167(12):7119-25
– reference: 11169409 - Eur J Immunol. 2000 Dec;30(12):3663-71
– reference: 21795651 - Neurology. 2011 Aug 9;77(6):580-8
– reference: 24700511 - Ann Neurol. 2014 Mar;75(3):411-28
– reference: 25821844 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 19;2(3):e89
– reference: 15259004 - Eur J Immunol. 2004 Aug;34(8):2072-83
– reference: 18209026 - J Immunol. 2008 Feb 1;180(3):1326-37
– reference: 17121989 - Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18697-702
– reference: 9202313 - J Neurochem. 1997 Jul;69(1):214-22
– reference: 26637427 - Acta Neuropathol Commun. 2015 Dec 04;3:80
– reference: 18050272 - Eur J Immunol. 2008 Jan;38(1):299-308
– reference: 11782255 - Immunol Rev. 2001 Oct;183:159-72
– reference: 23876060 - Immunology. 2013 Dec;140(4):456-64
– reference: 25798445 - Neurol Neuroimmunol Neuroinflamm. 2015 Mar 12;2(2):e81
– reference: 24610298 - Neuropediatrics. 2014 Jun;45(3):196-9
– reference: 27181546 - Intern Med. 2016;55(10 ):1351-4
– reference: 26869529 - Mult Scler. 2016 Oct;22(12 ):1541-1549
– reference: 21928277 - Eur J Immunol. 2012 Jan;42(1):217-27
– reference: 21880773 - J Virol. 2011 Nov;85(21):11038-47
– reference: 26593750 - Eur J Neurol. 2016 Mar;23 (3):580-7
– reference: 26209592 - Mult Scler. 2016 Mar;22(3):312-9
– reference: 27793206 - J Neuroinflammation. 2016 Sep 27;13(1):280
– reference: 12732654 - J Exp Med. 2003 May 5;197(9):1073-81
– reference: 25662345 - Mult Scler. 2015 Oct;21(12):1513-20
– reference: 21169067 - Clin Immunol. 2011 Mar;138(3):247-54
– reference: 26922251 - Brain Dev. 2016 Aug;38(7):690-3
– reference: 15589308 - Lancet. 2004 Dec 11-17;364(9451):2106-12
– reference: 8864286 - Brain Pathol. 1996 Jul;6(3):303-11
– reference: 26957602 - Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):3323-8
– reference: 26918533 - Dev Med Child Neurol. 2016 Aug;58(8):836-41
– reference: 10580814 - J Neuroimmunol. 1999 Nov 1;101(1):61-7
– reference: 4179459 - Exp Neurol. 1968 Dec;22(4):545-55
– reference: 20033986 - Ann Neurol. 2009 Dec;66(6):833-42
– reference: 12578856 - Int Immunol. 2003 Feb;15(2):261-8
– reference: 8675668 - J Clin Invest. 1995 Dec;96(6):2966-74
– reference: 12115610 - Eur J Immunol. 2002 Jul;32(7):1905-13
– reference: 7688186 - Am J Pathol. 1993 Aug;143(2):555-64
– reference: 9804377 - Brain Pathol. 1998 Oct;8(4):681-94
– reference: 25815356 - Ann Clin Transl Neurol. 2015 Mar;2(3):295-301
– reference: 12244307 - Nat Immunol. 2002 Oct;3(10):944-50
– reference: 27802825 - J Neuroinflammation. 2016 Nov 1;13(1):281
– reference: 16461459 - Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2280-5
– reference: 24014878 - J Immunol. 2013 Oct 1;191(7):3594-604
– reference: 24045088 - J Neurol Sci. 2013 Dec 15;335(1-2):221-3
– reference: 24685353 - Acta Neuropathol Commun. 2014 Mar 31;2:35
– reference: 17237795 - Nat Med. 2007 Feb;13(2):211-7
– reference: 27766432 - Acta Neuropathol. 2017 Feb;133(2):223-244
– reference: 10384097 - J Immunol. 1999 Jul 1;163(1):40-9
– reference: 21177754 - Mult Scler. 2011 Mar;17(3):297-302
– reference: 26041801 - Mult Scler. 2016 Feb;22(2):174-84
– reference: 12817030 - J Immunol. 2003 Jul 1;171(1):455-61
– reference: 1997396 - Immunology. 1991 Jan;72(1):127-32
– reference: 20410464 - Neurology. 2010 May 25;74(21):1711-5
– reference: 27144216 - Neurol Neuroimmunol Neuroinflamm. 2016 Apr 14;3(3):e225
– reference: 11063818 - J Neuroimmunol. 2000 Nov 1;111(1-2):23-33
– reference: 12817031 - J Immunol. 2003 Jul 1;171(1):462-8
– reference: 22204662 - J Neuroinflammation. 2011 Dec 28;8:184
– reference: 26000330 - Ann Clin Transl Neurol. 2015 May;2(5):581-93
– reference: 11024537 - J Neuroimmunol. 2000 Oct 2;110(1-2):83-96
– reference: 22914827 - Neurology. 2012 Sep 18;79(12):1273-7
– reference: 8367453 - Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7990-4
– reference: 17142321 - Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):19057-62
– reference: 2462020 - J Neurochem. 1989 Jan;52(1):296-304
– reference: 27788675 - J Neuroinflammation. 2016 Sep 26;13(1):279
– reference: 10556797 - Eur J Immunol. 1999 Nov;29(11):3432-9
– reference: 20129932 - Brain. 2010 Feb;133(Pt 2):333-48
– reference: 12843245 - J Neurosci. 2003 Jul 2;23(13):5461-71
– reference: 26907324 - Viruses. 2016 Feb 12;8(2):null
– reference: 2430983 - J Cell Biol. 1986 Dec;103(6 Pt 1):2439-48
– reference: 11390515 - J Immunol. 2001 Jun 15;166(12):7588-99
– reference: 26498263 - Mult Scler. 2016 Jun;22(7):964-8
– reference: 19001173 - Arch Neurol. 2008 Nov;65(11):1527-32
– reference: 2445777 - J Neuroimmunol. 1987 Dec;17(1):61-9
– reference: 27306633 - Neurology. 2016 Jul 12;87(2):229-31
– reference: 19540601 - J Neuroimmunol. 2009 Aug 18;213(1-2):60-8
– reference: 26516628 - Neurol Neuroimmunol Neuroinflamm. 2015 Oct 15;2(6):e163
– reference: 27022743 - Acta Neuropathol. 2016 Jul;132(1):43-58
– reference: 27128728 - Neuropediatrics. 2016 Aug;47(4):245-52
– reference: 9653093 - J Exp Med. 1998 Jul 6;188(1):169-80
– reference: 22493449 - J Biol Chem. 2012 May 18;287(21):17206-13
– reference: 438816 - J Neurochem. 1979 May;32(5):1451-60
– reference: 9739061 - J Clin Invest. 1998 Sep 15;102(6):1265-73
– reference: 3734801 - J Neurochem. 1986 Sep;47(3):779-89
– reference: 23579868 - Acta Neuropathol. 2013 Jun;125(6):815-27
– reference: 27147513 - J Neurol. 2016 Jul;263(7):1349-60
– reference: 26347141 - J Cell Biol. 2015 Sep 14;210(6):891-8
– reference: 23257621 - Mult Scler. 2013 Jul;19(8):1052-9
– reference: 15634682 - J Biol Chem. 2005 Mar 11;280(10):8985-93
– reference: 2450462 - Am J Pathol. 1988 Mar;130(3):443-54
– reference: 25121570 - J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72
– reference: 16955141 - J Clin Invest. 2006 Sep;116(9):2393-402
– reference: 19175799 - Immunology. 2009 Sep;128(1 Suppl):e250-61
– reference: 27802824 - J Neuroinflammation. 2016 Nov 1;13(1):282
– reference: 17255324 - Am J Pathol. 2007 Feb;170(2):557-66
– reference: 16955140 - J Clin Invest. 2006 Sep;116(9):2385-92
– reference: 26869530 - Mult Scler. 2016 Dec;22(14 ):1821-1829
– reference: 16306341 - Diabetes. 2005 Dec;54 Suppl 2:S52-61
– reference: 1695240 - J Neurochem. 1990 Aug;55(2):583-7
– reference: 23128668 - Mult Scler. 2013 Jun;19(7):941-6
– reference: 17573820 - J Neurochem. 2007 Sep;102(6):1853-62
– reference: 25681455 - Neurology. 2015 Mar 17;84(11):1177-9
– reference: 26163068 - Mult Scler. 2016 Apr;22(4):470-82
– reference: 25749692 - J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):446-8
– reference: 16172404 - Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13992-7
– reference: 10443879 - Ann Neurol. 1999 Aug;46(2):144-60
– reference: 19487416 - J Exp Med. 2009 Jun 8;206(6):1303-16
– reference: 23733879 - J Immunol. 2013 Jul 1;191(1):117-26
– reference: 26185777 - Neurol Neuroimmunol Neuroinflamm. 2015 Jul 02;2(4):e131
– reference: 12925695 - J Clin Invest. 2003 Aug;112(4):544-53
– reference: 28331892 - Neurol Neuroimmunol Neuroinflamm. 2017 Mar 14;4(3):e335
– reference: 25364774 - Neurol Neuroimmunol Neuroinflamm. 2014 Oct 29;1(4):e40
– reference: 24935259 - J Exp Med. 2014 Jun 30;211(7):1465-83
– reference: 8943561 - Int Immunol. 1996 Nov;8(11):1667-74
– reference: 26587556 - Neurol Neuroimmunol Neuroinflamm. 2015 Nov 04;2(6):e175
– reference: 25434485 - BMC Neurol. 2014 Nov 30;14:224
– reference: 24323356 - J Exp Med. 2013 Dec 16;210(13):2921-37
– reference: 25520558 - Magn Reson Insights. 2014 Nov 09;7:23-31
– reference: 12060766 - Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8207-12
– reference: 58035 - J Immunol. 1976 May;116(5):1439-46
– reference: 24133290 - J Neurol Neurosurg Psychiatry. 2014 Apr;85(4):456-61
– reference: 23821341 - J Neuroimmune Pharmacol. 2013 Dec;8(5):1251-64
– reference: 20573031 - Neuropathology. 2011 Apr;31(2):101-11
– reference: 22279107 - J Immunol. 2012 Mar 1;188(5):2084-92
– reference: 21146219 - Mol Immunol. 2011 Jun;48(11):1332-7
SSID ssj0000493335
Score 2.5525868
SecondaryResourceType review_article
Snippet Myelin oligodendrocyte glycoprotein (MOG), a member of the immunoglobulin (Ig) superfamily, is a myelin protein solely expressed at the outermost surface of...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 529
SubjectTerms autoantibodies
demyelination
Immunology
inflammation
MOG
myelin oligodendrocyte glycoprotein
Title Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases
URI https://www.ncbi.nlm.nih.gov/pubmed/28533781
https://www.proquest.com/docview/1901767598
https://pubmed.ncbi.nlm.nih.gov/PMC5420591
https://doaj.org/article/97a0a8271ac14daeb1eb1456c599e4c3
Volume 8
WOSCitedRecordID wos000400710400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: DOA
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1664-3224
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000493335
  issn: 1664-3224
  databaseCode: M~E
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwEB7BCiQuiDfhsTISFw5R87Bjmxuwu8BhFw6L1JtxJjYEtelq267Uy_52xna3tAjBBSmJlMROrM8T-7Nm8g3AS0VDnObC57IWLueKd7ktUORt24gWlfWywZhsQp6cqPFYf95K9RViwpI8cAJupKUtrKpkabHknaWhhTaa9VFo7ThGnc9C6q3F1I_Ee-u6FskvSaswPfL9dLoMoVxBslBERvlrHopy_X_imL-HSm7NPUd34PaaNLI3qbF34Zob7sHNlEZydR--Hq_CX-Xs06SnVaYLEgS4Wjj2frLCWRRi6IfX7MBhfxb_9vvGLDuNEeCMan0cPFnFNHrbqdA0PsuGaGh2kLw38wfw5ejw9N2HfJ05IUfeVIvc-Uo7VXouvegEbzVBiLylU4eeN16oVrYl0gyGkjqxI1bQhPy2jaZdFq5-CHvDbHCPgdmuqQvbBZmvjhMdsoQttliVjcXCYp3B6ApHg2tZ8ZDdYmJoeRGQNxF5E5A3EfkMXm1qnCVJjb-UfRu6ZlMuiGHHC2QiZm0i5l8mksGLq4419PEEj4gd3Gw5N4ENBTUbrTJ4lDp686qKiEwtVZmB3DGBnbbs3hn671GgW_CKWGv55H80_incCnDEGEv1DPYW50v3HG7gxaKfn-_DdTlW-9H26Xh8efgTYugMvA
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Myelin+Oligodendrocyte+Glycoprotein%3A+Deciphering+a+Target+in+Inflammatory+Demyelinating+Diseases&rft.jtitle=Frontiers+in+immunology&rft.au=Peschl%2C+Patrick&rft.au=Bradl%2C+Monika&rft.au=H%C3%B6ftberger%2C+Romana&rft.au=Berger%2C+Thomas&rft.date=2017-05-08&rft.issn=1664-3224&rft.eissn=1664-3224&rft.volume=8&rft.spage=529&rft_id=info:doi/10.3389%2Ffimmu.2017.00529&rft_id=info%3Apmid%2F28533781&rft.externalDocID=28533781
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-3224&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-3224&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-3224&client=summon